ATE345327T1 - Verfahren zur herstellung von amorphem atorvastatin kalzium - Google Patents
Verfahren zur herstellung von amorphem atorvastatin kalziumInfo
- Publication number
- ATE345327T1 ATE345327T1 AT00973115T AT00973115T ATE345327T1 AT E345327 T1 ATE345327 T1 AT E345327T1 AT 00973115 T AT00973115 T AT 00973115T AT 00973115 T AT00973115 T AT 00973115T AT E345327 T1 ATE345327 T1 AT E345327T1
- Authority
- AT
- Austria
- Prior art keywords
- atorvastatin calcium
- amorphous atorvastatin
- producing amorphous
- crude
- amorphous
- Prior art date
Links
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 title abstract 5
- 229960001770 atorvastatin calcium Drugs 0.000 title abstract 5
- 238000004519 manufacturing process Methods 0.000 title 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 229960005370 atorvastatin Drugs 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000001816 cooling Methods 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000001953 recrystallisation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9903634A HU226640B1 (en) | 1999-10-18 | 1999-10-18 | Process for producing amorphous atorvastatin calcium salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE345327T1 true ATE345327T1 (de) | 2006-12-15 |
Family
ID=90014241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00973115T ATE345327T1 (de) | 1999-10-18 | 2000-10-17 | Verfahren zur herstellung von amorphem atorvastatin kalzium |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1235800B1 (de) |
| JP (1) | JP2003512354A (de) |
| KR (1) | KR100664353B1 (de) |
| CN (1) | CN1157374C (de) |
| AT (1) | ATE345327T1 (de) |
| AU (1) | AU1166301A (de) |
| CA (1) | CA2388018C (de) |
| CZ (1) | CZ300071B6 (de) |
| DE (1) | DE60031882T2 (de) |
| HR (1) | HRP20020334B1 (de) |
| HU (1) | HU226640B1 (de) |
| PL (1) | PL354604A1 (de) |
| RS (1) | RS50473B (de) |
| RU (1) | RU2255932C2 (de) |
| SK (1) | SK286861B6 (de) |
| UA (1) | UA72777C2 (de) |
| WO (1) | WO2001028999A1 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| DE10135493A1 (de) * | 2001-07-20 | 2003-01-30 | Jobst Krauskopf | Pharmazeutische Zusammensetzung zur Behandlung von Hypercholesterinämie |
| RU2304139C2 (ru) | 2001-07-30 | 2007-08-10 | Д-р Редди'с Лабораторис Лтд | Кристаллические формы vi и vii кальциевой соли аторвастатина |
| RU2309141C2 (ru) * | 2002-03-18 | 2007-10-27 | Байокон Лимитид | АМОРФНЫЕ ИНГИБИТОРЫ ГМГ-КоА-РЕДУКТАЗЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ |
| HUP0500074A3 (en) * | 2002-03-18 | 2005-07-28 | Biocon Ltd Bangalore | Amorphous hmg-coa reductase inhibitors of desired particle size and process for producing them |
| ITMI20020907A1 (it) * | 2002-04-29 | 2003-10-29 | Chemi Spa | Processo di preparazione della forma amorfa del sale di calcio della atorvastatina |
| AU2002356423A1 (en) * | 2002-05-28 | 2003-12-12 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
| HU227041B1 (en) * | 2003-03-24 | 2010-05-28 | Richter Gedeon Nyrt | Process for the synthesis of amorphous atorvastatin calcium |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| US7655692B2 (en) * | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| CZ298382B6 (cs) * | 2004-03-10 | 2007-09-12 | Zentiva, A. S. | Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace |
| AU2004317570B2 (en) | 2004-03-17 | 2011-01-06 | Ranbaxy Laboratories Limited | Process for the production of atorvastatin calcium in amorphous form |
| CA2562844A1 (en) * | 2004-04-16 | 2005-10-27 | Pfizer Products Inc. | Process for forming amorphous atorvastatin calcium |
| CN1692906A (zh) * | 2004-04-30 | 2005-11-09 | 鲁南制药集团股份有限公司 | 治疗高血脂症的组合物 |
| US7875731B2 (en) | 2004-05-05 | 2011-01-25 | Pfizer Inc. | Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid |
| AU2005263550C1 (en) * | 2004-07-16 | 2013-01-17 | Lek Pharmaceuticals D.D. | Oxidative degradation products of atorvastatin calcium |
| JP2008506764A (ja) | 2004-07-20 | 2008-03-06 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態 |
| US7674923B2 (en) * | 2004-09-28 | 2010-03-09 | Teva Pharmaceutical Industries Ltd | Process for preparing forms of atorvastatin calcium substantially free of impurities |
| KR20070054730A (ko) * | 2004-10-18 | 2007-05-29 | 테바 파마슈티컬 인더스트리즈 리미티드 | 알콜 및 케톤 및/또는 에스테르의 혼합물인 유기 용매에아토르바스타틴 헤미-칼슘 염을 용해시키고 용매를제거하여 비결정형 아토르바스타틴 헤미-칼슘을 제조하는방법 |
| CA2585836A1 (en) | 2004-10-28 | 2006-05-04 | Warner-Lambert Company Llc | Process for forming amorphous atorvastatin |
| WO2007057755A1 (en) | 2005-11-21 | 2007-05-24 | Warner-Lambert Company Llc | Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid magnesium |
| EP1810667A1 (de) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmazeutische Zusammensetzung enthaltend amorphes Atorvastatin |
| KR100833439B1 (ko) * | 2007-01-02 | 2008-05-29 | 씨제이제일제당 (주) | 비결정형 아토르바스타틴 칼슘의 개선된 제조방법 |
| CZ201039A3 (cs) | 2010-01-19 | 2011-07-27 | Zentiva, K. S | Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme |
| HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
| CN102424663B (zh) * | 2010-12-03 | 2013-08-14 | 天津滨江药物研发有限公司 | 一种阿托伐他汀氨基酸盐及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| ATE123020T1 (de) * | 1990-05-11 | 1995-06-15 | American Cyanamid Co | N-acylierte arylpyrrole als insektizide, akarizide, nematizide und molluskizide wirkstoffe. |
| HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
| HU224196B1 (hu) * | 1996-09-20 | 2005-06-28 | Meiji Seika Kaisha Ltd. | Cefditoren-pivoxil kristályos formája, és eljárás annak előállítására |
-
1999
- 1999-10-18 HU HU9903634A patent/HU226640B1/hu not_active IP Right Cessation
-
2000
- 2000-10-17 DE DE60031882T patent/DE60031882T2/de not_active Expired - Fee Related
- 2000-10-17 RS YUP-283/02A patent/RS50473B/sr unknown
- 2000-10-17 EP EP00973115A patent/EP1235800B1/de not_active Expired - Lifetime
- 2000-10-17 AU AU11663/01A patent/AU1166301A/en not_active Abandoned
- 2000-10-17 KR KR1020027004906A patent/KR100664353B1/ko not_active Expired - Fee Related
- 2000-10-17 HR HR20020334A patent/HRP20020334B1/xx not_active IP Right Cessation
- 2000-10-17 CZ CZ20021256A patent/CZ300071B6/cs not_active IP Right Cessation
- 2000-10-17 CN CNB008144583A patent/CN1157374C/zh not_active Expired - Fee Related
- 2000-10-17 AT AT00973115T patent/ATE345327T1/de not_active IP Right Cessation
- 2000-10-17 WO PCT/HU2000/000106 patent/WO2001028999A1/en not_active Ceased
- 2000-10-17 JP JP2001531799A patent/JP2003512354A/ja active Pending
- 2000-10-17 PL PL00354604A patent/PL354604A1/xx not_active Application Discontinuation
- 2000-10-17 SK SK519-2002A patent/SK286861B6/sk not_active IP Right Cessation
- 2000-10-17 CA CA002388018A patent/CA2388018C/en not_active Expired - Fee Related
- 2000-10-17 UA UA2002054059A patent/UA72777C2/uk unknown
- 2000-10-17 RU RU2002113564/04A patent/RU2255932C2/ru not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001028999A1 (en) | 2001-04-26 |
| KR100664353B1 (ko) | 2007-01-02 |
| CN1379760A (zh) | 2002-11-13 |
| SK5192002A3 (en) | 2002-11-06 |
| CA2388018A1 (en) | 2001-04-26 |
| DE60031882D1 (de) | 2006-12-28 |
| HUP9903634A2 (hu) | 2001-12-28 |
| RU2255932C2 (ru) | 2005-07-10 |
| RS50473B (sr) | 2010-03-02 |
| JP2003512354A (ja) | 2003-04-02 |
| CZ20021256A3 (cs) | 2002-08-14 |
| AU1166301A (en) | 2001-04-30 |
| HK1050199A1 (en) | 2003-06-13 |
| PL354604A1 (en) | 2004-01-26 |
| HUP9903634A3 (en) | 2002-01-28 |
| KR20020063166A (ko) | 2002-08-01 |
| EP1235800A1 (de) | 2002-09-04 |
| CZ300071B6 (cs) | 2009-01-21 |
| DE60031882T2 (de) | 2007-07-05 |
| HRP20020334B1 (hr) | 2007-12-31 |
| YU28302A (sh) | 2005-06-10 |
| CA2388018C (en) | 2008-04-08 |
| CN1157374C (zh) | 2004-07-14 |
| HUP9903634D0 (en) | 1999-12-28 |
| UA72777C2 (en) | 2005-04-15 |
| HRP20020334A2 (en) | 2004-02-29 |
| HU226640B1 (en) | 2009-05-28 |
| EP1235800B1 (de) | 2006-11-15 |
| SK286861B6 (sk) | 2009-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60031882D1 (de) | Verfahren zur herstellung von amorphem atorvastatin kalzium | |
| ATE362759T1 (de) | Verfahren zur herstellung von amorphem atorvastatin kalzium | |
| ATE243672T1 (de) | Neue thyroid-rezeptorliganden und verfahren | |
| DE59407982D1 (de) | Verfahren zur Gewinnung von Tocopherolen und Sterolen aus natürlichen Quellen | |
| DE69907210D1 (de) | Glucocorticoid- und thyroidhormonrezeptor-liganden zur behandlung von stoffwechselkrankheiten | |
| DE69706135D1 (de) | Verfahren zur Herstellung Simvastatin von Lovastatin oder Mevinolinsäure | |
| JP2003512354A5 (de) | ||
| DE69606495D1 (de) | Verfahren zur Herstellung von depolymerisiertem Naturkautschuk | |
| ES2191628T3 (es) | Procedimiento para extraccion y purificacion de paclitaxel a partir de fuentes naturales. | |
| DE60008540D1 (de) | Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen | |
| ATE216231T1 (de) | Verfahren zur herstellung von avermectin/zein- zusammensetzungen | |
| ATE466015T1 (de) | Verfahren zur herstellung von phenserin und dessen analogon | |
| DE69405396D1 (de) | Verfahren zur synthese von nukleinsäuren auf einem festträger und verbindungen verwendbar als festträger in diesem verfahren | |
| DE69513847D1 (de) | Verfahren zur herstellung von substituierten 3-aminobenzonitrilen | |
| DE69400343D1 (de) | Neues Verfahren zur Herstellung von 6alpha, 9alphadifluoro-Sterioden und Zwischenprodukte davon | |
| DE69426979D1 (de) | Verfahren zur herstellung von hiv-proteasehemmern | |
| DE59609108D1 (de) | Verfahren zur herstellung eines kristallinen polymorphs von terazosin-hydrochlorid | |
| DE69828166D1 (de) | Verfahren zur herstellung von mit radioaktivem iod markierten, neurorezeptor-wirksamen mitteln | |
| ATE270690T1 (de) | Verfahren zur wiedergewinnung von polyestern oder polyestergemischen | |
| ATE146166T1 (de) | Verfahren zur herstellung von 2,2,-dimethyl-3- ((z)-2- (alkoxycarbonyl)ethenyl)cyclopropancarbonsäuree tern und zwischenprodukte | |
| Cerreti et al. | A novel synthesis of tricyclic-fused hydrindene–azetidinone compounds by sequential Mn (III)-promoted 4-exo-trig cyclization/radical aromatic substitution | |
| ATE325797T1 (de) | Verfahren zur herstellung von hochreinem triethylendiamin | |
| ATE376554T1 (de) | Verfahren zur herstellung von sterol- und stanol- estern | |
| ATE231858T1 (de) | Verfahren zur herstellung von 3-substituierten 4- phenyl-piperidin derivaten | |
| ATE231485T1 (de) | Verfahren zur herstellung von arylmalonaten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |